Malignant Pheocromocytoma: Rare, Aggressive, but Easily Neglected Abstract #679

Introduction: Pheocromocytomas are rare neuroendocrine tumors of which only 10% present metastatic disease.
Aim(s): We report a case of an 81-year-old hypertensive patient complaining of dizziness, fatigue and nosebleed.
Materials and methods: Imaging techniques rulled out pulmonary embolism and showed pericardial effusion, loculated ascitis (peritoneal carcinomatosis?), mediastinic adenopathies and two nodules compatible with accessory spleens. The ascitic fluid revealed 1,700 leucocites/uL (1088 neutrophilis/uL) and no neoplastic cells. Moreover, repeated paroxysms of tremor, impressive cyanosis of face, thorax and extremities without hypoxemia, with immensurable arterial pressure were witnessed, self-limited to 30 minutes; the patient denied headaches and dyspnea. He recalled similar episodes during the previous two months.
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: Ana Catarina Ribeiro

To read results and conclusion, please login ...

Further abstracts you may be interested in

#142 The role of 18F DOPA-PET in a case of malignant pheochromcytoma
Introduction: Pheocromocytoma is a rare tumor arising from chromaffin cells of adrenal medullary or extra adrenal paraganglionic tissue. Histological criteria cannot differentiate benign from malignant pheocromocytomas. The diagnosis of a malignant pheocromocytoma requires local invasion, recurrence and documented metastatic disease. The radionuclide scanning (123I - 131I-MIBG) is a fundamental diagnostic tool used to confirm the biochemical and radiological diagnosis of pheochromocytoma. In fact, MIBG scanning may confirm that the visualised lesion in an adrenal gland is indeed a pheochromocytoma and detect extra-adrenal paraganglionic tissue. However, MIBG scans are negative in around 15% of benign pheochromocytomas and in up to 50% of malignant ones. Other radionuclide techniques (18FDG-PET, 18F-DOPA-PET, 18F-FDA-PET) have been successfully used in investigation of pheochromocytomas. 18F-DOPA-PET and 18F-FDA-PET have been reported to be highly sensitive and specific for benign pheochromocytomas, while 18FDG-PET can be useful for malignant lesions with higher metabolic activity.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof. Laura De Marinis
#1296 The Application of Octreotide in a SINET Patient with Carcinoid Syndrome, Carcinoid Heart Disease and Carcinoid Crisis: A Case Report
Introduction: In Chinese population, small intestinal neuroendocrine tumor (SINET) only accounts for 2.2% of gastroenteropancreatic NET, while carcinoid syndrome, carcinoid heart disease (CHD) and carcinoid crisis are rarer.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Luohai Chen
Authors: Chen L, Zhang Y, Chen M, Chen J, ...
#124 Management and outcomes of malignant paragangliomas and phaeochromocytomas
Introduction: Chromaffin-cell tumors include phaeochromocytomas and paragangliomas, represent a rare group of neuroendocrine tumors and are located in adrenal medulla or extra-adrenal sites, respectively. Ten percent of phaeochromocytomas and 15-35% of paragangliomas are malignant.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: DR Christos Toumpanakis
#796 Somatostatin Analogues for Preventing Carcinoid Crisis
Introduction: Carcinoid crisis is a life-threating syndrome of neuroendocrine tumors (NETs) and is characterized by dramatic blood pressure fluctuation, arrhythmias, and bronchospasm. Somatostatin analogues (SSTA) have been recommended for prophylactic administration before provocative procedures.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: LinJie Guo
Authors: Guo L, Tang C, ...
#546 Treatment of Malignant Neuroendocrine Tumors of the Hepatopancreatododenal Region
Introduction: The incidence of malignant NETs of the hepatopancreatoduodenal region is currently set at 10-15 cases per 100,000 people. Patient treatment and prognosis differ from those with adenocarcinoma.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Ivan Vasiliev
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.